Thursday, October 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 1, 2026

Nokia accelerates AI-RAN momentum with new partnerships driving path to AI-Native 6G #MWC26

View original at globenewswire.com
Nokia accelerates AI-RAN momentum with new partnerships driving path to AI-Native 6G #MWC26 Press Release Nokia accelerates AI-RAN momentum with new partnerships driving path to AI-Native 6G #MWC26 Nokia announces significant progress in its strategic AI-RAN partnership with NVIDIA, including new customer integrations…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI is the new workload reshaping networks requiring architectural change across every layer including the radio

    80% confidence
  • DOCOMO aims to deliver a more advanced, differentiated, and superior customer experience through AI-Centric Network strategy

    80% confidence
  • Physical AI requires an intelligent network underpinned by AI-RAN so operators can fully harness distributed intelligence across every layer

    80% confidence
  • The addition of leading operators and partners signals that AI-RAN is gaining traction and has become a strategic direction for the industry

    80% confidence
  • Dell PowerEdge provides a smooth, cost-effective path from 5G-advanced to 6G with no-touch software upgrades and low-touch silicon upgrades

    80% confidence
  • External AI workload integration through AITRAS Orchestrator is important for telecommunications operators to maximize the value of their compute resources

    80% confidence
  • Completion of GPU-accelerated RAN tests marks a step up in maturity for AI-RAN technology

    80% confidence
  • AI-RAN is being explored as part of longer-term evolution of BT's radio access network for potential benefits in performance, resilience, and operational simplicity

    80% confidence
  • A common cloud-native foundation powered by Red Hat OpenShift is essential for faster ROI and accelerating delivery of AI-native 6G

    80% confidence
  • AI is entering the next evolution that goes far beyond being a network add-on, forming the nucleus of future autonomous AI-native and 6G-ready networks

    80% confidence
  • The telecommunications industry has opportunity to build networks as fully software-driven systems instead of upgrading in big hardware-heavy cycles

    80% confidence
  • Indosat's commitment is to ensure every Indonesian can benefit from the digital and AI era with no one left behind

    80% confidence
  • AI-RAN is a key enabler for optimizing end-to-end network performance and advancing toward AI-native 6G and physical AI

    80% confidence
  • The over-the-air demonstration at T-Mobile's AI-RAN Innovation Center provided valuable insight into how AI and RAN workloads can operate together on shared infrastructure

    80% confidence
  • The momentum behind AI-RAN signals a fundamental shift in how mobile networks are designed and deployed

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com